Inhibitex Soars on Early HCV Data; Phase II Combos Next
Shares of Inhibitex Inc. skyrocketed a whopping 130 percent Friday after top-line data from an early hepatitis C virus (HCV) study indicated INHX-189's potential as a monotherapy, putting the Atlanta-based company hot on the trail of the interferon-free HCV regimen vanguard.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST